^
Association details:
| Biomarker: | MSLN expression |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | RG7600 (Microtubule inhibitor, Mesothelin-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I Study of DMOT4039A, an Antibody–Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
Excerpt:
One remarkable response includes a 65-year-old male patient with pancreatic cancer and liver metastases...Archival tumor tissue (from a liver biopsy) showed IHC 2+ staining for mesothelin. This patient received DMOT4039A at a dose of 2.4 mg/kg q3w, with the first partial response noted after cycle 12 and confirmed at subsequent scan 1 month later.
DOI:
https://doi.org/10.1158/1535-7163.MCT-15-0693
